- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Metastatic (Stage IV) HER2 positive breast cancer; Metastatic (Stage IV) HER2 positive adenocarcinoma of the stomach or gastroesophageal junction; Early HER2 positive breast cancer
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 313KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 51KB)
Trastuzumab – November 2021
Trastuzumab: Powder for I.V. infusion 440 mg; Herzuma®
Last updated
4 March 2022